Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more
Market Cap & Net Worth: Bioventix PLC (51B)
Bioventix PLC (F:51B) has a market capitalization of $85.27 Million (€83.08 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #19838 globally and #2116 in its home market, demonstrating a -4.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioventix PLC's stock price €15.90 by its total outstanding shares 5224860 (5.22 Million).
Bioventix PLC Market Cap History: 2017 to 2026
Bioventix PLC's market capitalization history from 2017 to 2026. Data shows change from $123.85 Million to $85.27 Million (-5.74% CAGR).
Bioventix PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioventix PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.42x
Bioventix PLC's market cap is 8.42 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
14.57x
Bioventix PLC's market cap is 14.57 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $123.85 Million | $7.25 Million | $4.92 Million | 17.09x | 25.16x |
| 2018 | $151.25 Million | $8.75 Million | $5.66 Million | 17.28x | 26.71x |
| 2019 | $176.11 Million | $9.29 Million | $5.86 Million | 18.96x | 30.04x |
| 2020 | $225.19 Million | $10.31 Million | $7.20 Million | 21.83x | 31.26x |
| 2021 | $194.41 Million | $10.93 Million | $6.73 Million | 17.79x | 28.88x |
| 2022 | $220.38 Million | $11.72 Million | $7.67 Million | 18.80x | 28.72x |
| 2023 | $250.28 Million | $12.82 Million | $8.37 Million | 19.53x | 29.89x |
| 2024 | $199.51 Million | $13.61 Million | $8.10 Million | 14.66x | 24.64x |
| 2025 | $110.48 Million | $13.12 Million | $7.58 Million | 8.42x | 14.57x |
Competitor Companies of 51B by Market Capitalization
Companies near Bioventix PLC in the global market cap rankings as of March 18, 2026.
Key companies related to Bioventix PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Bioventix PLC Historical Marketcap From 2017 to 2026
Between 2017 and today, Bioventix PLC's market cap moved from $123.85 Million to $ 85.27 Million, with a yearly change of -5.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €85.27 Million | -22.82% |
| 2025 | €110.48 Million | -44.62% |
| 2024 | €199.51 Million | -20.28% |
| 2023 | €250.28 Million | +13.57% |
| 2022 | €220.38 Million | +13.36% |
| 2021 | €194.41 Million | -13.67% |
| 2020 | €225.19 Million | +27.87% |
| 2019 | €176.11 Million | +16.44% |
| 2018 | €151.25 Million | +22.12% |
| 2017 | €123.85 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bioventix PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $85.27 Million USD |
| MoneyControl | $85.27 Million USD |
| MarketWatch | $85.27 Million USD |
| marketcap.company | $85.27 Million USD |
| Reuters | $85.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.